Path ID: DB00942_MESH_D010300_1
Concepts
| Identifier | Name | Type |
|---|---|---|
| MESH:C012262 | cycrimine | Drug |
| UniProt:P11229 | Muscarinic acetylcholine receptor M1 | Protein |
| GO:0007271 | synaptic transmission, cholinergic | BiologicalProcess |
| GO:0014055 | acetylcholine secretion, neurotransmission | BiologicalProcess |
| MESH:D010300 | Parkinson’s disease | Disease |
Relationships
NOTE: predicates are annotated in Biolink Model (v1.3.0)
| Subject | Predicate | Object |
|---|---|---|
| Cycrimine | NEGATIVELY REGULATES | Muscarinic Acetylcholine Receptor M1 |
| Muscarinic Acetylcholine Receptor M1 | POSITIVELY REGULATES | Synaptic Transmission, Cholinergic |
| Synaptic Transmission, Cholinergic | INCREASES ACTIVITY OF | Acetylcholine Secretion, Neurotransmission |
| Acetylcholine Secretion, Neurotransmission | POSITIVELY CORRELATED WITH | Parkinson’S Disease |
Comment: In Parkinson’s disease, there is imbalance between levels of acetylcholine and dopamine, where increased levels of acetylcholine and degeneration of dopaminergic pathways are observed. Therefore, muscarinic antagonists block central cholinergic activity and balance out neurotransmitters in the brain (https://en.wikipedia.org/wiki/Muscarinic_antagonist#Effects). Anticholinergic drugs may also be prescribed to improve bladder dysfunction (https://pubmed.ncbi.nlm.nih.gov/20370804/).
Reference: